Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Kymera Therapeutics, Inc. < Previous 1 2 Next > Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update November 02, 2023 From Kymera Therapeutics, Inc. Via GlobeNewswire Tickers KYMR Kymera Therapeutics to Participate in Upcoming November Investor Conferences November 01, 2023 From Kymera Therapeutics, Inc. Via GlobeNewswire Tickers KYMR Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi October 27, 2023 From Kymera Therapeutics, Inc. Via GlobeNewswire Tickers KYMR Kymera Therapeutics to Report Third Quarter 2023 Financial Results on November 2 October 26, 2023 From Kymera Therapeutics, Inc. Via GlobeNewswire Tickers KYMR Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma October 16, 2023 From Kymera Therapeutics, Inc. Via GlobeNewswire Tickers KYMR Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma September 18, 2023 From Kymera Therapeutics, Inc. Via GlobeNewswire Tickers KYMR Kymera Therapeutics to Participate in Upcoming September Investor Conferences August 28, 2023 From Kymera Therapeutics, Inc. Via GlobeNewswire Tickers KYMR Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update August 03, 2023 From Kymera Therapeutics, Inc. Via GlobeNewswire Tickers KYMR Kymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3 July 27, 2023 From Kymera Therapeutics, Inc. Via GlobeNewswire Tickers KYMR Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia June 22, 2023 From Kymera Therapeutics, Inc. Via GlobeNewswire Tickers KYMR Kymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials June 14, 2023 From Kymera Therapeutics, Inc. Via GlobeNewswire Tickers KYMR Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 June 09, 2023 From Kymera Therapeutics, Inc. Via GlobeNewswire Tickers KYMR Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, Compared to Small Molecule Inhibitor in Preclinical Leukemia Models at the European Hematology Association Congress June 09, 2023 From Kymera Therapeutics, Inc. Via GlobeNewswire Tickers KYMR Kymera Therapeutics to Participate in Upcoming June Investor Conference June 01, 2023 From Kymera Therapeutics, Inc. Via GlobeNewswire Tickers KYMR Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer May 22, 2023 From Kymera Therapeutics, Inc. Via GlobeNewswire Tickers KYMR Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253 May 19, 2023 From Kymera Therapeutics, Inc. Via GlobeNewswire Tickers KYMR Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium May 18, 2023 From Kymera Therapeutics, Inc. Via GlobeNewswire Tickers KYMR Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update May 04, 2023 From Kymera Therapeutics, Inc. Via GlobeNewswire Tickers KYMR Kymera Therapeutics to Report First Quarter 2023 Financial Results on May 4 April 11, 2023 From Kymera Therapeutics, Inc. Via GlobeNewswire Tickers KYMR Kymera Therapeutics to Participate in Upcoming March Investor Conferences March 01, 2023 From Kymera Therapeutics, Inc. Via GlobeNewswire Tickers KYMR Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update February 23, 2023 From Kymera Therapeutics, Inc. Via GlobeNewswire Tickers KYMR Kymera Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 23 February 01, 2023 From Kymera Therapeutics, Inc. Via GlobeNewswire Tickers KYMR Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company January 10, 2023 From Kymera Therapeutics, Inc. Via GlobeNewswire Tickers KYMR Kymera Appoints Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary January 04, 2023 From Kymera Therapeutics, Inc. Via GlobeNewswire Tickers KYMR Kymera Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 January 03, 2023 From Kymera Therapeutics, Inc. Via GlobeNewswire Tickers KYMR Kymera Announces Positive Results from Phase 1 Clinical Trial Evaluating KT-474 in Patients with HS and AD and Sanofi’s Decision to Advance KT-474 into Phase 2 Clinical Trials December 14, 2022 From Kymera Therapeutics, Inc. Via GlobeNewswire Tickers KYMR Preclinical Data from Kymera Therapeutics’ Collaborations Demonstrate Therapeutic Potential of STAT3 Degraders in CTCL and IRAKIMiD Combination with BCL-2 Inhibitor in MYD88-Mutant DLBCL at the American Society of Hematology Annual Meeting December 12, 2022 From Kymera Therapeutics, Inc. Via GlobeNewswire Tickers KYMR Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting December 11, 2022 From Kymera Therapeutics, Inc. Via GlobeNewswire Tickers KYMR Kymera Therapeutics Provides Webcast Information for December 14 Investor Event December 01, 2022 From Kymera Therapeutics, Inc. Via GlobeNewswire Tickers KYMR Kymera Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Business Update November 03, 2022 From Kymera Therapeutics, Inc. Via GlobeNewswire Tickers KYMR < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
